WUHNOTCHealthcare · Drug Manufacturers - Specialty & Generic

Wuhan General Group (China), Inc.

$0.00+0.00%(+$0.00)

TickerSpark Score

54/100

Mixed

100

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WUHN research report →

52-Week Range50% of range

Low $0.00

Current $0.00

High $0.00

Companywuhn.org

Wuhan General Group (China), Inc. , through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies.

CEO: Jeffrey Robinson
IPO: 2006
Employees: 700
HQ: Pointe-Claire, QC, CA

Price Chart

+200.00% · this period

Valuation

Market Cap: $16.55K
P/E: -0.01
P/S: 1.17
P/B: 0.03
EV/EBITDA: 0.00
Div Yield: 0.00%

Profitability

Gross Margin: 9.70%
Op Margin: -11882.90%
Net Margin: -12086.93%
ROE: -316.07%
ROIC: -254.74%

Growth & Income

Revenue: $14.18K · -57.40%
Net Income: $-1,713,443 · -517.92%
EPS: $-0.03 · -494.94%
Op Income: $-1,684,520
FCF YoY: -3251.25%

Performance & Tape

52W High: $0.00
52W Low: $0.00
50D MA: $0.00
200D MA: $0.00
Beta: -2.60
Avg Volume: 1.74K

Get TickerSpark's AI analysis on WUHN

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime